Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
83.00
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
September 03, 2024
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
August 16, 2024
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
August 15, 2024
From
AstraZeneca
Via
Business Wire
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
August 14, 2024
AstraZeneca, T-Mobile US, and Intuitive Surgical are hitting all-time highs, driven by solid sector performance, robust earnings, and strategic advancements.
Via
MarketBeat
Topics
ETFs
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
July 29, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
July 26, 2024
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu.
Via
MarketBeat
Topics
ETFs
AstraZeneca’s H1 and Q2 2024 Financial Results
July 25, 2024
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
June 25, 2024
From
AstraZeneca
Via
Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Eli Lilly's Stock Surge Driven by GLP-1 Demand
June 20, 2024
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
June 17, 2024
From
AstraZeneca
Via
Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
June 16, 2024
From
AstraZeneca
Via
Business Wire
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
June 12, 2024
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
June 10, 2024
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
June 02, 2024
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
June 02, 2024
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 02, 2024
From
AstraZeneca
Via
Business Wire
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
May 27, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
May 23, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
May 22, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From
AstraZeneca
Via
Business Wire
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19, 2024
From
AstraZeneca
Via
Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
May 02, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
May 01, 2024
From
AstraZeneca
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.